SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-001219
Filing Date
2024-02-27
Accepted
2024-02-27 17:15:10
Documents
14
Period of Report
2024-02-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm   iXBRL 8-K 30025
  Complete submission text file 0001683168-24-001219.txt   205448

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cnsp-20240221.xsd EX-101.SCH 3018
3 XBRL LABEL FILE cnsp-20240221_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE cnsp-20240221_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3730
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 24688449
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)